These results indicated that the dual suppression of PI3K/Akt/mTOR and TAK1 pathways by NVP-BEZ235 and PP242 may link to their greater anticancer activity, and NVP-BEZ235 may be an optimal candidate as mTOR inhibitor for combination therapy in RCC. The gene discussed is AKT1; the disease is renal cell carcinoma.